BioCentury | Jan 9, 2018
Distillery Therapeutics

Autoimmune disease

...II testing of VTP-38543, liver X receptor β (NR1H2; LXRβ) agonist, to treat atopic dermatitis. Ralexar Therapeutics Inc....
BioCentury | Jan 4, 2018
Preclinical News

Cholesterol efflux in phagocytes may promote remyelination

...indications. However, Rgenix Inc. (New York, N.Y.) is developing LXR agonists for cancer indications, and Ralexar Therapeutics Inc....
...is expected to acquire Sucampo this quarter (see BioCentury Extra, Dec. 26, 2017) . Allison Johnson Myelin VTS-270 Mallinckrodt plc Ralexar Therapeutics Inc. Rgenix...
BioCentury | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Liver X receptor (LXR)

...and sphingolipid storage, in Phase II/III testing to treat Niemann-Pick disease type C1 (NPC1) . Alexar Therapeutics...
BioCentury | Dec 7, 2015
Clinical News

ALX-101: Phase IIa started

...U.S. Phase IIa trial of 2 dose levels of ALX-101 topical gel in 72 patients. Alexar Therapeutics...
BioCentury | Feb 5, 2015
Finance

PPPs holding steady

...Therapeutics Inc. Neurology; Gene/Cell therapy Cambridge, Mass. $45.0 CRISPR Therapeutics Gene/Cell therapy Basel, Switzerland $25.0 Alexar Therapeutics...
...Medical College (founder) Research institute; university Affinivax Inc. Infectious U.S. Boston Children's Hospital (technology) Hospital Alexar Therapeutics...
BioCentury | Jan 6, 2014
Financial News

Alexar Therapeutics completes venture financing

Alexar Therapeutics Inc. , Malvern, Pa. Business: Dermatology Date completed: 1/2/14 Type: Venture financing Raised: $21.5 million Investors: New Science Ventures; Third Point; Palo Alto Investors WIR Staff Dermatology...
BioCentury | Jan 6, 2014
Finance

X marks the spot

...X marks the spot Alexar Therapeutics Inc. isn't going after a novel target - LXR has been...
BioCentury | Jan 3, 2014
Financial News

Alexar debuts with $21.5 million in series A

Alexar Therapeutics Inc. (Malvern, Pa.) debuted with $21.5 million secured in a series A round led by New Science Ventures and Third Point Ventures. Palo Alto Investors also participated. Alexar is developing liver X receptor...
Items per page:
1 - 8 of 8
BioCentury | Jan 9, 2018
Distillery Therapeutics

Autoimmune disease

...II testing of VTP-38543, liver X receptor β (NR1H2; LXRβ) agonist, to treat atopic dermatitis. Ralexar Therapeutics Inc....
BioCentury | Jan 4, 2018
Preclinical News

Cholesterol efflux in phagocytes may promote remyelination

...indications. However, Rgenix Inc. (New York, N.Y.) is developing LXR agonists for cancer indications, and Ralexar Therapeutics Inc....
...is expected to acquire Sucampo this quarter (see BioCentury Extra, Dec. 26, 2017) . Allison Johnson Myelin VTS-270 Mallinckrodt plc Ralexar Therapeutics Inc. Rgenix...
BioCentury | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Liver X receptor (LXR)

...and sphingolipid storage, in Phase II/III testing to treat Niemann-Pick disease type C1 (NPC1) . Alexar Therapeutics...
BioCentury | Dec 7, 2015
Clinical News

ALX-101: Phase IIa started

...U.S. Phase IIa trial of 2 dose levels of ALX-101 topical gel in 72 patients. Alexar Therapeutics...
BioCentury | Feb 5, 2015
Finance

PPPs holding steady

...Therapeutics Inc. Neurology; Gene/Cell therapy Cambridge, Mass. $45.0 CRISPR Therapeutics Gene/Cell therapy Basel, Switzerland $25.0 Alexar Therapeutics...
...Medical College (founder) Research institute; university Affinivax Inc. Infectious U.S. Boston Children's Hospital (technology) Hospital Alexar Therapeutics...
BioCentury | Jan 6, 2014
Financial News

Alexar Therapeutics completes venture financing

Alexar Therapeutics Inc. , Malvern, Pa. Business: Dermatology Date completed: 1/2/14 Type: Venture financing Raised: $21.5 million Investors: New Science Ventures; Third Point; Palo Alto Investors WIR Staff Dermatology...
BioCentury | Jan 6, 2014
Finance

X marks the spot

...X marks the spot Alexar Therapeutics Inc. isn't going after a novel target - LXR has been...
BioCentury | Jan 3, 2014
Financial News

Alexar debuts with $21.5 million in series A

Alexar Therapeutics Inc. (Malvern, Pa.) debuted with $21.5 million secured in a series A round led by New Science Ventures and Third Point Ventures. Palo Alto Investors also participated. Alexar is developing liver X receptor...
Items per page:
1 - 8 of 8